Synthesis and Property of Multifunctional Non-Viral Gene Vectors Based on [12]Anen3
Qian Wang,Xu-Ying Liu,Fang Tang,Zhong-Lin Lu
DOI: https://doi.org/10.1360/tb-2022-0216
2022-01-01
Abstract:In 1972, Theodore Friedmann formally proposed the concept of gene therapy in the journal of Science. The proposal of gene therapy brought important opportunities for the complete cure of human genetic diseases and major diseases. The process from concept to clinical application was long and tortuous. Until the early 1990s, the NIH of the USA conducted the first clinical study of a rare immunodeficiency disease, which resulted in the explosive expansion of gene therapy. Unfortunately, a patient with ornithine carbamyltransferase deficiency produced an immune response during the treatment of gene therapy, and he eventually died. Since then, gene therapy has entered a cold winter. These setbacks have propelled basic research in immunology, virology, cell biology and targeted diseases. In the early 2000s, mRNA and siRNA have been developed rapidly for gene therapy, and the 2006 Nobel Prize in Physiology or Medicine was awarded to Andrew Fire and Craig Mello for their discovery of RNA interference. These accelerated the development of gene therapy again. In the following years, viral gene vectors began to enter clinical trials. In 2012, the world's first gene therapy drug came out, which was called Glybera. It enlarged the application prospect of gene therapy. Gene editing technology won the 2020 Nobel Prize in Chemistry, and the clinical application of gene therapy has received more and more attention. So far, more than 2000 clinical studies have been carried out, it is widely used in diseases ranging from single gene diseases to complex neurodegenerative diseases. By the beginning of 2021, 18 gene therapy drugs have been launched around the world, with a market value of over $7 billion. However, compared with people's expectations, the development of gene therapy is relatively slow, and a key factor is the lack of safe and efficient gene carriers, especially non-viral gene carriers. Their low transfection efficiency is due to their inability to effectively overcome the multiple physiological barriers in the process of gene delivery. Therefore, scientists have tried to develop multifunctional non-viral gene carriers. Over the past decade, a variety of non-viral gene vectors have developed tremendously. Our research group has been committed to developing safe and efficient multi-functional non-viral gene vectors in recent years. Using [12]aneN(3) as positive unit, we took advantage of the structural tunability of the non-viral gene carrier, introduced fluorescence imaging units, stimulus-response units and targeting units to synthesize a series of multifunctional non-viral gene carriers. Their transfection performance and transfection process for pDNA and siRNA were studied by gel electropherogram assay, cytotoxicity, cell uptake, organelle escape, transfection experiment and various fluorescence imaging techniques. We have found some non-viral gene vectors with good biocompatibility and high gene transfection efficiency, so we further studied their potential in theranostics, combined therapy, etc. In conclusion, we have made good foundation and great progress in construction and research of multifunctional non-viral gene vectors, and it is expected to achieve clinical application. Therefore, this paper will summarize the work progress of our research group in the design and synthesis of multifunctional non-viral gene carriers with [12]aneN(3) as positive unit and their transfection property study. We also made the perspective view to the challenges and future development of non-viral gene carriers.